구조모아 (StructureMoa)항암 chemical structure spider web
방문분석
큐레이션 브리핑
anti-VEGF (ranibizumab). wet AMD 표준. Eylea와 head-to-head·주기·real-world persistence.
Intravitreal anti-VEGF Fab (ranibizumab) for wet AMD, RVO, DME, and diabetic retinopathy; established ophthalmology biologic.
기전. Ranibizumab is a humanized Fab fragment that binds all isoforms of VEGF-A, preventing VEGFR activation and reducing neovascularization and retinal edema.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
VEGF-A
Wet AMD, DME, RVO, myopic CNV
Global
Approved
lucentis · ranibizumab · Lucentis · Byooviz · Cimerli
2026-09-10
Data Confidence · High
Development Signal · Established
bispecific antibodies like faricimab that simultaneously target VEGF a
Novel metrics that included Visual Acuity Recovery Rate (VARR), Time to 1
구조화 데이터
Novel metrics that included Visual Acuity Recovery Rate (VARR), Time to 1
Anatomic non-response and fibrotic disease; switch/combination with other anti-VEGF agents.
bispecific antibodies like faricimab that simultaneously target VEGF a
VEGF-A · biomarker of treatment response, supporting further validation in larger independent cohorts
Ranibizumab is a humanized Fab fragment that binds all isoforms of VEGF-A, preventing VEGFR activation and reducing neovascularization and retinal edema.
apoptosis, and VEGF-A levels were evaluated using confocal microscopy, plate reader-based assays, and ELISA techniques
biomarker of treatment response, supporting further validation in larger independent cohorts
Anatomic non-response and fibrotic disease; switch/combination with other anti-VEGF agents.
구조화 데이터
mouse
9
BCVA and CST on OCT
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
분석
큐레이션 브리핑
anti-VEGF (ranibizumab). wet AMD 표준. Eylea와 head-to-head·주기·real-world persistence.
Intravitreal anti-VEGF Fab (ranibizumab) for wet AMD, RVO, DME, and diabetic retinopathy; established ophthalmology biologic.
기전. Ranibizumab is a humanized Fab fragment that binds all isoforms of VEGF-A, preventing VEGFR activation and reducing neovascularization and retinal edema.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
VEGF-A
Wet AMD, DME, RVO, myopic CNV
Global
Approved
lucentis · ranibizumab · Lucentis · Byooviz · Cimerli
2026-09-10
Data Confidence · High
Development Signal · Established
bispecific antibodies like faricimab that simultaneously target VEGF a
Novel metrics that included Visual Acuity Recovery Rate (VARR), Time to 1
구조화 데이터
Novel metrics that included Visual Acuity Recovery Rate (VARR), Time to 1
Anatomic non-response and fibrotic disease; switch/combination with other anti-VEGF agents.
bispecific antibodies like faricimab that simultaneously target VEGF a
VEGF-A · biomarker of treatment response, supporting further validation in larger independent cohorts
Ranibizumab is a humanized Fab fragment that binds all isoforms of VEGF-A, preventing VEGFR activation and reducing neovascularization and retinal edema.
apoptosis, and VEGF-A levels were evaluated using confocal microscopy, plate reader-based assays, and ELISA techniques
biomarker of treatment response, supporting further validation in larger independent cohorts
Anatomic non-response and fibrotic disease; switch/combination with other anti-VEGF agents.
구조화 데이터
mouse
9
BCVA and CST on OCT
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.